Table of Contents
Peptide Structure and Synthetic Origin
BPC-157's amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, typically expressed in its free-acid form. The sequence contains three consecutive proline residues — an unusual structural feature that confers significant resistance to enzymatic degradation, as proline-rich regions are poor substrates for most endoproteases.
The synthetic origin of BPC-157 is well-documented: it corresponds to a defined segment within the sequence of the human gastric juice protein BPC (Body Protection Compound), from which it was originally isolated and characterized. The synthetic form used in research is manufactured by solid-phase peptide synthesis (SPPS) and does not contain any biological material from natural sources.
BPC-157 has a molecular weight of approximately 1419.5 Da and is soluble in aqueous systems at physiologically relevant pH ranges. Its relatively small size makes it comparatively straightforward to synthesize at high purity, which is why it has been available as a research tool for an extended period and is represented in a larger body of preclinical literature than many newer, more structurally complex peptides.
Research History and Publication Landscape
BPC-157 has been studied in controlled preclinical settings since the early 1990s. The primary research groups contributing to the published literature on BPC-157 are based largely in Croatia, with additional publications from research groups across Europe and Asia. The compound has accumulated one of the larger bodies of preclinical research literature among synthetic peptides available for laboratory use.
Published studies have investigated BPC-157 across a range of tissue and organ system models, including gastrointestinal tract preparations, musculoskeletal tissue models, vascular preparations, and neurological pathway contexts. The breadth of model systems represented in the literature makes BPC-157 relevant to a correspondingly wide range of laboratory research applications.
Researchers building literature reviews should note that the BPC-157 publication landscape is primarily preclinical — the compound has not progressed to published Phase 2 or Phase 3 clinical trials as of early 2026, though Phase 1 clinical investigation has been initiated. Framing research questions accordingly and distinguishing between in vitro, ex vivo, and in vivo preclinical findings is important for appropriate contextualisation.
Molecular Pathways Under Investigation
Multiple molecular mechanisms have been proposed and studied in connection with BPC-157's observed effects in preclinical models. The most extensively characterised areas include:
Angiogenic signalling: Published studies have documented BPC-157's interactions with the nitric oxide (NO) system and with vascular endothelial growth factor (VEGF) signalling pathways in tissue preparation models. Modulation of these pathways has been proposed as a mechanism through which BPC-157 may influence tissue vascularization in preclinical contexts.
Growth factor receptor interactions: Research has examined BPC-157's effects on EGF receptor pathways and on the expression of various growth factors in tissue culture models. The compound's interaction with the growth hormone receptor and downstream signalling components has also been studied.
Extracellular matrix biology: In connective tissue and musculoskeletal research contexts, BPC-157 has been studied for its interactions with tendon fibroblast populations and matrix remodelling pathways. Preclinical models examining tendon, ligament, and bone tissue have been particularly well represented in the published literature.
Researchers should access the primary literature directly to evaluate the specific model systems, concentrations, and endpoints used in these studies before designing their own experimental protocols.
Stability and Solution Characteristics
BPC-157 is supplied as a lyophilized powder and demonstrates reasonable stability in the dry state when stored under appropriate conditions. Long-term storage of lyophilized BPC-157 is recommended at -20°C or below, protected from light and moisture. The compound's three-proline motif contributes to its resistance to enzymatic degradation in solution, but thermal stability of reconstituted solutions should not be assumed.
In solution, BPC-157 is most commonly prepared in sterile water, bacteriostatic water, or physiological saline for research applications. The reconstitution guide in this Research Hub provides step-by-step guidance on reconstituting lyophilized peptides including reconstitution volumes and storage of prepared solutions.
Reconstituted BPC-157 solutions should be stored at 2–8°C and used within a timeframe consistent with published stability data for the specific vehicle used. Repeated freeze-thaw cycles of reconstituted solutions are not recommended. For detailed storage guidance applicable to research peptides broadly, the peptide storage guide covers all key parameters.
BPC-157 Alongside TB-500 in Research
In research contexts, BPC-157 and TB-500 (Thymosin Beta-4 fragment 17-23) are frequently studied in parallel due to overlapping areas of preclinical interest, particularly in connective tissue and musculoskeletal research models. While the two compounds have distinct structures and primary mechanisms, their complementary research profiles have led to significant interest in their combined use in laboratory study designs.
TB-500 is a synthetic peptide corresponding to the actin-binding region of Thymosin Beta-4, a protein involved in actin sequestration, cell migration, and wound healing signalling. Researchers designing studies that span both compounds should carefully review the distinct pharmacological profiles of each before designing combination protocols.
Both BPC-157 and TB-500 are available in the healing research category. Researchers can view BPC-157 10mg and TB-500 10mg on their respective product pages.
Quality Documentation Requirements
BPC-157's relatively straightforward structure — compared to acylated or modified peptides — means that standard HPLC purity data, supported by mass spectrometry confirmation, is generally sufficient for identity and purity verification. Researchers should expect:
- HPLC purity ≥98% — by area under the chromatogram, with chromatogram image provided
- MS confirmation — observed mass consistent with BPC-157 molecular weight (~1419.5 Da); the three-proline sequence creates a characteristic MS fragmentation pattern that experienced analysts can verify
- Lot number and testing date — for batch traceability
- Third-party testing — independent laboratory documentation is the quality standard for research-grade material
The COA reading guide and the lab testing page provide additional context on how to evaluate quality documentation for BPC-157 and other research peptides.
Sourcing BPC-157 for Canadian Laboratories
BPC-157 is available from Peptides Canada as BPC-157 10mg, supplied for research and laboratory use with HPLC-verified purity and third-party testing documentation. The compound ships domestically within Canada, eliminating international customs complexity for Canadian laboratory researchers.
For questions about documentation standards, available lot information, or comparative compound selection for specific research designs, reach out through the contact page. Common sourcing and handling questions are addressed in the FAQ. To browse the full catalog of research compounds including BPC-157, TB-500, and other healing-category peptides, visit the product catalog or the healing collection.